Maribavir: Interim Phase II data

ViroPharma disclosed on its 1Q13 earnings call that interim data from 36 patients with asymptomatic CMV infection in a European Phase II trial showed that twice-daily

Read the full 268 word article

How to gain access

Continue reading with a
two-week free trial.